Evidence map›Paper›PMID 38074820›Full record

ArticleAmerican journal of translational research2023

Successful treatment of new-onset diabetes mellitus and IgA nephropathy after COVID-19 vaccination: a case report.

Li-Hui Qu, An-Qi Zhang, Gui-Jun Xu, Xue-Lian Wang, Hong-Qing Lou, Jia-Jia Lou, Hong Jiang, Xu-Qing Zhu

Open access · greenAbstract readCase Reports
In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Li-Hui QuKidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, Zhejiang, P. R. China.
An-Qi ZhangKidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, Zhejiang, P. R. China.
Gui-Jun XuDepartment of Nephrology, Yiwu Central Hospital Yiwu, Zhejiang, P. R. China.
Xue-Lian WangDepartment of Nephrology, Yiwu Central Hospital Yiwu, Zhejiang, P. R. China.
Hong-Qing LouDepartment of Nephrology, Yiwu Central Hospital Yiwu, Zhejiang, P. R. China.
Jia-Jia LouDepartment of Nephrology, Yiwu Central Hospital Yiwu, Zhejiang, P. R. China.
Hong JiangKidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, Zhejiang, P. R. China.
Xu-Qing ZhuDepartment of Nephrology, Yiwu Central Hospital Yiwu, Zhejiang, P. R. China.
Yiwu Science and Technology Research Institute · CNHangzhou Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

De novo glomerular injuries or relapse of nephropathy following COVID-19 vaccine has been reported. Here we present the first case of successful treatment of new-onset diabetes mellitus and biopsy-proven IgA nephropathy after COVID-19 vaccination. A 56-year-old man with no known medical history of renal dysfunction or diabetes mellitus developed both within 3 months after receiving a third dose of inactivated COVID-19 vaccine (Vero cells). His symptoms were characterized by brown urine, severe dry mouth, and excessive thirst. Randomly acquired blood glucose levels exceeded 33.3 mmol/L. A kidney biopsy showed IgA nephropathy. He was started on insulin for glycemic control. After glucocorticoid and cyclophosphamide treatment, oral tablets of repaglinide, combined with acarbose, controlled blood glucose and stabilized kidney function. This case is unique because the kidneys and pancreas were simultaneously affected by the vaccine. Successful treatment of the disease proved that cyclophosphamide combined with glucocorticoids were effective and that blood glucose was successfully controlled. This treatment option could be useful in similar cases in the future.

Indexed as

COVID-19COVID-19 vaccineIgA nephropathynew-onset diabetes

Identifiers

PMID38074820
PMCPMC10703642
OpenAlexW4389803069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.